Limaprost

• Description :

  Limaprost (OP1206) is a PGE1 analogue and a potent and orally active vasodilator. Limaprost increases blood flow and inhibits platelet aggregation. Limaprost pain relief, has antianginal effects, and can be used for ischaemic symptoms research[1][2].

• Product Name Alternative :

  17α,20-dimethyl-δ2-PGE1; ONO1206; OP1206

• UNSPSC :

  12352211

• Hazard Statement :

  H300

• Target :

  PGE synthase

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/Limaprost.html

• Purity :

  99.91

• Solubility :

  DMSO : ≥ 40 mg/mL

• Smiles :

  O=C(O)/C=C/CCCC[C@@H]1[C@@H](/C=C/[C@@H](O)C[C@@H](C)CCCC)[C@H](O)CC1=O

• Molecular Formula :

  C22H36O5

• Molecular Weight :

  380.52

• Precautions :

  H300

• References & Citations :

  [1]Tsuboi T, et al. Pharmacological evaluation of OP 1206, a prostaglandin E1 derivative, as an antianginal agent. Arch Int Pharmacodyn Ther. 1980 Sep;247 (1) :89-102.|[2]Swainston Harrison T, et al. Limaprost. Drugs. 2007;67 (1) :109-18; discussion 119-20.|[3]Murata K, et al. PGE1 Attenuates IL-1β-induced NGF Expression in Human Intervertebral Disc Cells. Spine (Phila Pa 1976) . 2016 Jun;41 (12) :E710-6.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [74397-12-9]